Articles dans des revues avec comité de lecture (396)
  1. 229. Klastersky, J., Awada, A., Aoun, M., & Paesmans, M. (2009). Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended? Current opinion in oncology, 21(4), 297-302. doi:10.1097/CCO.0b013e32832c9651
  2. 230. Kaufman, B., Trudeau, M., Awada, A., Blackwell, K., Bachelot, T., Salazar, V., DeSilvio, M., Westlund, R., Zaks, T., Spector, N., & Johnston, S. (2009). Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet oncology, 10(6), 581-588. doi:10.1016/S1470-2045(09)70087-7
  3. 231. Otrock, Z. K., Hatoum, H. A., Awada, A., Ishak, R. S., & Shamseddine, A. I. (2009). Hypoxia-inducible factor in cancer angiogenesis: structure, regulation and clinical perspectives. Critical reviews in oncology/hematology, 70(2), 93-102. doi:10.1016/j.critrevonc.2009.01.001
  4. 232. Awada, A., & De Castro, S. (2009). Head and neck cancer emerging strategies: advances and new challenges. Current opinion in oncology, 21(3), 191-193. doi:10.1097/CCO.0b013e32832a6e05
  5. 233. Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., & Jusko, W. J. (2009). Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients. Cancer chemotherapy and pharmacology, 63(6), 1049-1063. doi:10.1007/s00280-008-0827-2
  6. 234. Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., & Jusko, W. J. (2009). Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer chemotherapy and pharmacology, 63(6), 1035-1048. doi:10.1007/s00280-008-0828-1
  7. 235. Vora, T. S., de Azambuja, E., Awada, A., & Piccart-Gebhart, M. (2009). Novel therapeutics in breast cancer-Looking to the future. Update on Cancer Therapeutics, 3(4), 189-205. doi:10.1016/j.uct.2009.07.001
  8. 236. Bauvet, F., Awada, A., Gil, T., & Hendlisz, A. (2009). Conséquences thérapeutiques des progrès de la biologie moléculaire en oncologie. Bulletin du cancer, 96(1), 59-71. doi:10.1684/bdc.2008.0796
  9. 237. Awada, A., Piccart-Gebhart, M., Jones, S. F., Peck, R. A., Gil, T., Lebwohl, D., Wu, C.-Y., & Burris, H. A. (2009). Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer chemotherapy and pharmacology, 63(3), 417-425. doi:10.1007/s00280-008-0751-5
  10. 238. Bellmunt, J., Négrier, S., Escudier, B., Awada, A., Aapro, M., & SIOG Taskforce, (2009). The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Critical reviews in oncology/hematology, 69(1), 64-72. doi:10.1016/j.critrevonc.2008.08.002
  11. 239. Prenen, H., Gil, T., & Awada, A. (2009). New therapeutic developments in renal cell cancer. Critical reviews in oncology/hematology, 69(1), 56-63. doi:10.1016/j.critrevonc.2008.07.007
  12. 240. Lalami, Y., de Castro, G., Bernard, C., & Awada, A. (2009). Management of head and neck cancer in elderly patients. Drugs & aging, 26(7), 571-583. doi:10.2165/11316340-000000000-00000
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>